However, recent studies have revealed that PD-L1 expression and tumor-infiltrating lymphocytes (TILs) are significantly higher in TNBC patients compared to other breast cancer subtypes, suggesting that TNBC exhibits strong immunogenicity and may be amenable to anti-PD-1/PD-L1 therapy [83,84]. The gene discussed is CD274; the disease is neoplasm.